<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768231</url>
  </required_header>
  <id_info>
    <org_study_id>RIAlta-1</org_study_id>
    <secondary_id>2020-003146-36</secondary_id>
    <nct_id>NCT04768231</nct_id>
  </id_info>
  <brief_title>Rifampicin at High Dose for Difficult-to-Treat Tuberculosis</brief_title>
  <acronym>RIAlta</acronym>
  <official_title>Safety of Rifampicin at High Dose for the Treatment of Adult Subjects With Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar De São João, E.P.E.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Enfermedades Respiratorias y del Ambiente, Paraguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of rifampicin given at a dose three times&#xD;
      as the standard one, in persons with tuberculosis that belong to groups that have not been&#xD;
      widely included in previous trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, one-arm, open-label trial to evaluate the safety of rifampicin at 35mg/kg per&#xD;
      day, added to the remaining standard first-line drugs, in subjects with tuberculosis&#xD;
      belonging to groups that have been underrepresented in previous trials: persons living with&#xD;
      HIV, older than 65 years, malnourished, diabetics, and chronic stable liver disease. The main&#xD;
      outcome is the rate of severe adverse events and adverse events leading to treatment&#xD;
      modification as compared to that in a historical cohort (patietns belonging to these groups&#xD;
      treated in the same centers from 2017-2019). Microbiological efficacy and extended follow-up&#xD;
      data until one year after treatment will also be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single intervention group compared with historical controls</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of rifampicin at 35mg/kg/day</measure>
    <time_frame>During the first 8 weeks after treatment start</time_frame>
    <description>Rate of grade 3 or higher adverse events as compared to that in historical controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of rifampicin at 35mg/kg/day in pulmonary tuberculosis</measure>
    <time_frame>At week 8 after treatment start</time_frame>
    <description>Rate of sputum liquid culture conversion (only pulmonary TB participants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of rifampicin at 35mg/kg/day</measure>
    <time_frame>During the first 8 weeks after treatment start</time_frame>
    <description>Rate of adverse events of any grade as compared to that in historical controls</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bactericidal activity in pulmonary tuberculosis</measure>
    <time_frame>During the first 8 weeks after treatment start</time_frame>
    <description>To describe the rate of sputum smear conversion, decline in bacterial load (measured as logCFU/mL), ant time-to-negative smear and culture.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics of rifampicin: Maximum concentration (Cmax)</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>To describe the Camx of rifampicin at 35mg/kg in the population included in the study. A spare-sample strategy sill be used with blood samples taken at 2, 4, and 6 hours after rifampicin administration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics of rifampicin: Time to maximum concentration (Tmax)</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>To describe the Tmax of rifampicin at 35mg/kg in the population included in the study. A spare-sample strategy sill be used with blood samples taken at 2, 4, and 6 hours after rifampicin administration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics of rifampicin: Area Under the Curve (AUC) 0-24</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>To describe the AUC0-24 of rifampicin at 35mg/kg in the population included in the study. A spare-sample strategy sill be used with blood samples taken at 2, 4, and 6 hours after rifampicin administration. The AUC 0-24h will be modelled accodring to the methods described in Magis-Escurrra et al, 2014.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacogenetics: analyze the variants in SLCO1B1, ABCB1, UGT1A, and PXR genes</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Analyze the polymorphisms in SLCO1B1, ABCB1, UGT1A, and PXR genes and their correlation with pharmacokinetic measures from previous outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics: correlate the AUC0-24/MIC ratio with culture conversion rate</measure>
    <time_frame>After 4 weeks of treatment (AUC0-24/MIC) and 8 weeks (culture conversion rate)</time_frame>
    <description>Correlate the pharmacokinetic measure AUC0-24 to the MIC (Minimum Inhibitory Concentration) ratio with the rate of culture conversion of sputum sample at 8 weeks in liquid culture medium.</description>
  </other_outcome>
  <other_outcome>
    <measure>AeoNose™ signature during treatment in pulmonary tuberculosis</measure>
    <time_frame>Baseline and weeks 1, 2, 4, 6 and 8.</time_frame>
    <description>Evaluate the response to treatment in the exhaled volatile particles signature by means of an electronic nose device: AeoNose™ (The eNose company, the Netherlands)</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of AeoNose™ with the bactericidal activity in pulmonary tuberculosis</measure>
    <time_frame>Baseline and weeks 1, 2, 4, 6 and 8.</time_frame>
    <description>Correlation of the changes in signature by means of an AeoNose™ and the changes in bacillary load during the first 8 weeks of treatment and the culture conversion rate at 8 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economics</measure>
    <time_frame>During the 6-month standard treatment period.</time_frame>
    <description>To describe tuberculosis associated costs and the incidence of catastrophic costs using the EUSAT-RCS questionnaire based on the WHO handbook for economic studies in tuberculosis in a subgroup of the participants.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>During the 6-month standard treatment period.</time_frame>
    <description>To describe the changes in quality of life during tuberculosis treatment using the SF-12 questionnaire and the St George's respiratory questionnaire (for pulmonary TB participants) of a subgroup of the included participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Extended follow-up: safety</measure>
    <time_frame>Up to 12 months after the end of TB treatment.</time_frame>
    <description>After the end of the intervention (8 weeks) data will be collected about severe (grade 3 or higher) or serious adverse events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Extended follow-up: cure, treatment failure, relapse</measure>
    <time_frame>Up to 12 months after the end of TB treatment.</time_frame>
    <description>After the end of the intervention (8 weeks) data will be collected about clinical outcomes as defined by the WHO (cure, treatment failure, relapse).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>R35HZE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with rifampicin at a dose of 35 mg per kilogram of body weight per day, added to the standard doses of isoniazid, pyrazinamide and ethambutol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>The target dose of 35mg/kg will be reached supplementing fixed-dose combination tablets (standard dose) with rifampin-only tablets.</description>
    <arm_group_label>R35HZE</arm_group_label>
    <other_name>Rifampicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        The participant must fulfill either criteria nr. 1-4 AND nr. 5 OR criteria nr. 1-4 AND 6,&#xD;
        AND anyone of 7-14:&#xD;
&#xD;
          1. Subjects with confirmed or probable pulmonary or extra pulmonary DS-TB.&#xD;
&#xD;
          2. Informed consent provided.&#xD;
&#xD;
          3. Positive smear, positive Xpert® MTB/RIF test, positive M. tuberculosis culture&#xD;
             (confirmed cases) OR histological study compatible with necrotizing granulomas OR a&#xD;
             liquid biochemistry (pleural, pericardial, ascites or cerebrospinal fluid) suggestive&#xD;
             of TB together with clinical symptoms resembling TB disease in the absence of any&#xD;
             other possible cause (probable cases).&#xD;
&#xD;
          4. Female participants of childbearing age must have a negative pregnancy test at&#xD;
             baseline.&#xD;
&#xD;
             AND&#xD;
&#xD;
          5. Age ≥ 60 years old. OR&#xD;
&#xD;
          6. Age ≥ 18 years AND one of the following&#xD;
&#xD;
          7. Body mass index ≤ 18.5&#xD;
&#xD;
          8. Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
          9. Diabetes Mellitus&#xD;
&#xD;
         10. Hepatitis C virus (HCV) infection (positive HCV serology)&#xD;
&#xD;
         11. Hepatitis B virus (HBV) infection (positive HBV surface antigen or anti-core&#xD;
             antibodies)&#xD;
&#xD;
         12. Daily alcohol intake ≥ 2 units of alcohol (1 unit of alcohol: 4% alcohol 250ml (ie&#xD;
             beer); 4.5% alcohol 218ml (i.e. cider); 13% alcohol 76ml (i.e. wine); 40% alcohol 25ml&#xD;
             (i.e. whisky))&#xD;
&#xD;
         13. Chronic liver disease of any other cause (metabolic, toxic, autoimmune)&#xD;
&#xD;
         14. Central Nervous System TB involvement&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Subjects will be excluded from entry if ANY ONE of the criteria listed below is met:&#xD;
&#xD;
          1. Rifampicin resistance confirmation.&#xD;
&#xD;
          2. Barthel index &lt;40 for subjects older than 60 years old.&#xD;
&#xD;
          3. Signs of significant liver disease:&#xD;
&#xD;
               -  Liver enzymes (AST or ALT) &gt; 5x upper limit of normal&#xD;
&#xD;
               -  Total bilirubin &gt; 3x upper limit of normal&#xD;
&#xD;
               -  Subjects with a Child-Pugh grade C cirrhosis or acute decompensation of their&#xD;
                  chronic liver disease at enrolment.&#xD;
&#xD;
               -  Any other grade 3-4 hepatobiliary alteration according to the CTCAE v5.&#xD;
&#xD;
          4. Subjects with known allergy or sensitivity to rifampicin, or any of the other&#xD;
             components of DS-TB treatment.&#xD;
&#xD;
          5. Treatment with any of the following: rifampicin, isoniazid, pyrazinamide, ethambutol,&#xD;
             levofloxacin, or moxifloxacin within the last month for at least 14 days or current TB&#xD;
             treatment for more than 7 days.&#xD;
&#xD;
          6. The subject is enrolled in any other investigational trial that includes a drug&#xD;
             intervention.&#xD;
&#xD;
          7. Subjects with solid organ transplantation or bone marrow transplantation.&#xD;
&#xD;
          8. Subjects with an active onco-hematological neoplasm requiring chemotherapy or immune&#xD;
             therapy.&#xD;
&#xD;
          9. Previous severe pulmonary disease, other than pulmonary DS-TB, according to local&#xD;
             investigator.&#xD;
&#xD;
         10. Pre-existing epilepsy or psychiatric disorder according to local investigator.&#xD;
&#xD;
         11. Ischemic heart disease OR severe arrhythmia within 6 months OR Atrial Fibrillation&#xD;
             with oral anticoagulant therapy indication when transitioning to low-molecular weight&#xD;
             heparin is not feasible.&#xD;
&#xD;
         12. Positive pregnancy test&#xD;
&#xD;
         13. Breastfeeding women.&#xD;
&#xD;
         14. The subject used any drugs or substances known to be strong inhibitors or inducers of&#xD;
             cytochrome P450 enzymes which are involved in the degradation pathways of rifampicin&#xD;
             within the time windows specified in table 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrián Sánchez-Montalvá, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d'Hebron University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrián Sánchez-Montalvá, PhD</last_name>
    <phone>+34 934893000</phone>
    <phone_ext>6090</phone_ext>
    <email>adrian.sanchez.montalva@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Espinosa-Pereiro, MD</last_name>
    <phone>+34 934893000</phone>
    <phone_ext>6090</phone_ext>
    <email>macspinosa@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Onno W. Akkerman, MD, PhD</last_name>
      <phone>+31 643436327</phone>
      <email>o.w.akkerman@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Cecile Magis-Escurra, PhD</last_name>
      <phone>+31246859770</phone>
      <email>cecile.magis-escurra@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias y del Ambiente</name>
      <address>
        <city>Asunción</city>
        <zip>1424</zip>
        <country>Paraguay</country>
      </address>
    </facility>
    <contact>
      <last_name>Arturo Battaglia, MD</last_name>
      <phone>+595975443343</phone>
      <email>arturombc@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gladys Molinas León, MD</last_name>
      <phone>+595975443343</phone>
      <email>gladys_molinasleon@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalario Universitario de Sao Joao</name>
      <address>
        <city>Porto</city>
        <zip>4202-451</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Margarida Tavares, MD, MPH</last_name>
      <phone>+351 963 565873</phone>
      <email>margaridaftavares@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Paraguay</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.eusattb.net/</url>
    <description>EUSAT consortium website</description>
  </link>
  <reference>
    <citation>van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin Infect Dis. 2011 May;52(9):e194-9. doi: 10.1093/cid/cir184. Review.</citation>
    <PMID>21467012</PMID>
  </reference>
  <reference>
    <citation>Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, van Crevel R, Aarnoutse R, Boeree M, Magis-Escurra C. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. PLoS One. 2019 Mar 14;14(3):e0213718. doi: 10.1371/journal.pone.0213718. eCollection 2019.</citation>
    <PMID>30870476</PMID>
  </reference>
  <reference>
    <citation>Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D, Nahid P. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2011 Mar;15(3):305-16. Review.</citation>
    <PMID>21333096</PMID>
  </reference>
  <reference>
    <citation>Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, Boeree MJ, Donders AR, van Altena R, van der Werf TS, Aarnoutse RE. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Int J Antimicrob Agents. 2014 Sep;44(3):229-34. doi: 10.1016/j.ijantimicag.2014.04.019. Epub 2014 Jun 9.</citation>
    <PMID>24985091</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rifampicin</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be available upn request to the EUSAT-consortium Steering Committee</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Since the end of the study; without specified limit.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

